I 
112TH CONGRESS 
1ST SESSION H. R. 2159 
To reduce disparities and improve access to effective and cost efficient diag-
nosis and treatment of prostate cancer through advances in testing, 
research, and education, including through telehealth, comparative effec-
tiveness research, and identification of best practices in patient education 
and outreach particularly with respect to underserved racial, ethnic and 
rural populations and men with a family history of prostate cancer, 
to establish a directive on what constitutes clinically appropriate prostate 
cancer imaging, and to create a prostate cancer scientific advisory board 
for the Office of the Chief Scientist at the Food and Drug Administration 
to accelerate real-time sharing of the latest research and accelerate 
movement of new medicines to patients. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 14, 2011 
Mr. TOWNS (for himself, Mr. BROUN of Georgia, Ms. FUDGE, Ms. RICHARD-
SON, Mr. GERLACH, Ms. MOORE, Mr. MCINTYRE, Mr. RANGEL, Ms. 
EDDIE BERNICE JOHNSON of Texas, Ms. WILSON of Florida, Ms. NOR-
TON, Mr. THOMPSON of Mississippi, Mr. CARSON of Indiana, Ms. LEE 
of California, Mr. ISRAEL, and Mr. KING of New York) introduced the 
following bill; which was referred to the Committee on Energy and Com-
merce, and in addition to the Committees on Veterans’ Affairs and 
Armed Services, for a period to be subsequently determined by the Speak-
er, in each case for consideration of such provisions as fall within the ju-
risdiction of the committee concerned 
A BILL 
To reduce disparities and improve access to effective and 
cost efficient diagnosis and treatment of prostate cancer 
through advances in testing, research, and education, 
including through telehealth, comparative effectiveness 
research, and identification of best practices in patient 
VerDate Mar 15 2010 
03:39 Jun 15, 2011
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6652
E:\BILLS\H2159.IH
H2159
rfrederick on DSKD9S0YB1PROD with BILLS
education and outreach particularly with respect to un-
derserved racial, ethnic and rural populations and men 
with a family history of prostate cancer, to establish 
a directive on what constitutes clinically appropriate 
prostate cancer imaging, and to create a prostate cancer 
scientific advisory board for the Office of the Chief Sci-
entist at the Food and Drug Administration to accelerate 
real-time sharing of the latest research and accelerate 
movement of new medicines to patients. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Prostate Research, 
Outreach, Screening, Testing, Access, and Treatment Ef-
fectiveness Act of 2011’’ or the ‘‘PROSTATE Act’’. 
SEC. 2. FINDINGS. 
Congress makes the following findings: 
(1) Prostate cancer is the second leading cause 
of cancer death among men. 
(2) In 2010, more than 217,730 new patients 
were diagnosed with prostate cancer and more than 
32,000 men died from this disease. 
(3) Roughly 2,000,000 Americans are living 
with a diagnosis of prostate cancer and its con-
sequences. 
(4) While prostate cancer generally affects older 
individuals, younger men are also at risk for the dis-
VerDate Mar 15 2010 
03:39 Jun 15, 2011
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2159.IH
H2159
rfrederick on DSKD9S0YB1PROD with BILLS